PRINT® Technology

A Simple Elegant Solution for Addressing Challenges in Drug Delivery

Pipeline

Advancing Product Candidates
from Our Own Pipeline

Partnerships

Actively Partnering with
World-class Collaborators

Liquidia Technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles. Our proprietary PRINT technology is a simple, elegant solution that solves common problems with drug delivery and efficacy. PRINT technology is a scalable cGMP compliant process that creates particles and can apply to virtually any therapeutic area, molecule or route of administration. Liquidia is bringing more efficient, controlled development capabilities to the industry while enhancing the safety and quality of products for patients. Liquidia is advancing product candidates from its own pipeline. These initial product candidates, LIQ861 and LIQ865, apply the PRINT technology to better drug delivery in inhaled and pain therapeutic areas, respectively. The PRINT technology is also licensed with world-leading pharmaceutical companies that are developing future product candidates.

Improving health with uniform drug particles

Liquidia is the only company in the world that precisely engineers drug particles in a virtually unlimited number of ways. Watch the video to see how we do it. The precision and simplicity of the PRINT technology can improve the efficacy, safety, and convenience of a wide range of medicines, while reducing manufacturing complexity and cost.

© 2017 Liquidia Technologies